Values as of: 2024-12-24
COMMON STOCK | Medical Devices |
Last Closing
USD 81.54Change
+0.14 (+0.17)%Market Cap
USD 103.90BVolume
2.47MAnalyst Target
USD 115.83Verdict
Verdict
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
Company Website : https://www.medtronic.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ABT | Abbott Laboratories |
+0.45 (+0.39%) |
USD 200.50B |
| ZBH | Zimmer Biomet Holdings Inc |
+0.48 (+0.45%) |
USD 21.51B |
| STE | STERIS plc |
+0.68 (+0.33%) |
USD 21.31B |
| GMED | Globus Medical |
+0.37 (+0.45%) |
USD 11.25B |
| SNN | Smith & Nephew SNATS Inc |
-0.10 (-0.41%) |
USD 10.75B |
| PEN | Penumbra Inc |
-0.19 (-0.08%) |
USD 9.31B |
| BIO | Bio-Rad Laboratories Inc |
+2.17 (+0.66%) |
USD 9.17B |
| BIO-B | Bio-Rad Laboratories Inc |
N/A |
USD 9.16B |
| GKOS | Glaukos Corp |
+2.86 (+1.93%) |
USD 8.32B |
| INSP | Inspire Medical Systems Inc |
-1.29 (-0.69%) |
USD 5.63B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| CYBG:LSE | VanEck Bionic Engineering.. | 9.75 % | 0.00 % |
+0.12 (+0.54%) |
N/A |
| CIB0:XETRA | VanEck Bionic Engineering.. | 9.50 % | 0.00 % |
N/A |
USD 4.87M |
| UMDV:SW | iShares US Medical Device.. | 9.28 % | 0.00 % |
N/A |
N/A |
| FLV | American Century ETF Trus.. | 5.39 % | 0.00 % |
+0.42 (+0.54%) |
N/A |
| PCIG | Litman Gregory Funds Trus.. | 5.31 % | 0.00 % |
+0.05 (+0.54%) |
USD 0.03B |
| FHI:CA | CI Health Care Giants Cov.. | 5.07 % | 0.75 % |
-0.01 (0.54%) |
CAD 0.08B |
| XUKS:LSE | db x-trackers FTSE 100 Sh.. | 4.27 % | 0.00 % |
-1.55 (0.54%) |
USD 7.29M |
| UTRN | Vesper U.S. Large Cap Sho.. | 4.07 % | 0.00 % |
+0.21 (+0.54%) |
USD 0.02B |
| DIVP | The Advisorsâ Inner .. | 3.81 % | 0.00 % |
+0.11 (+0.54%) |
USD 0.01B |
| DXQ:CA | Dynamic Active Enhanced Y.. | 2.53 % | 0.00 % |
+0.27 (+0.54%) |
N/A |
| GDVD | 2.46 % | 0.00 % |
N/A |
N/A | |
| PUD.B:CA | 1.85 % | 0.66 % |
N/A |
N/A | |
| TWAR | 1.11 % | 0.00 % |
N/A |
N/A | |
| JIGB | 0.45 % | 0.14 % |
N/A |
N/A | |
| SCHZ | Schwab U.S. Aggregate Bon.. | 0.01 % | 0.04 % |
+0.02 (+0.54%) |
USD 8.47B |
| BLV | Vanguard Long-Term Bond I.. | 0.00 % | 0.07 % |
-0.05 (0.54%) |
N/A |
| DTN | 0.00 % | 0.38 % |
N/A |
N/A | |
| IHI | iShares U.S. Medical Devi.. | 0.00 % | 0.43 % |
+0.43 (+0.54%) |
N/A |
| JDIV | J.P. Morgan Exchange-Trad.. | 0.00 % | 0.12 % |
+0.08 (+0.54%) |
N/A |
| VSDA | VictoryShares Dividend Ac.. | 0.00 % | 0.35 % |
+0.37 (+0.54%) |
USD 0.24B |
| AIIQ | 0.00 % | 0.79 % |
N/A |
N/A | |
| GDNA | 0.00 % | 0.00 % |
N/A |
N/A | |
| INAU | 0.00 % | 0.00 % |
N/A |
N/A | |
| HWF:CA | 0.00 % | 0.00 % |
N/A |
N/A | |
| FHI-B:CA | CI Health Care Giants Cov.. | 0.00 % | 0.00 % |
N/A |
CAD 0.05B |
| RXD | ProShares UltraShort Heal.. | 0.00 % | 0.77 % |
-0.13 (0.54%) |
N/A |
| RXD | ProShares UltraShort Heal.. | 0.00 % | 0.95 % |
-0.13 (0.54%) |
N/A |
| SICK | 0.00 % | 0.95 % |
N/A |
N/A | |
| VCLT | Vanguard Long-Term Corpor.. | 0.00 % | 0.07 % |
+0.01 (+0.54%) |
USD 15.44B |
| VCSH | Vanguard Short-Term Corpo.. | 0.00 % | 0.07 % |
-0.20 (0.54%) |
USD 35.42B |
| YLD | Principal Active High Yie.. | 0.00 % | 0.65 % |
+0.17 (+0.54%) |
USD 0.27B |
| LIFE:CA | Evolve Global Healthcare .. | 0.00 % | 0.69 % |
+0.13 (+0.54%) |
CAD 0.21B |
| OUFH:XETRA | 0.00 % | 0.00 % |
N/A |
N/A | |
| ABEQ | Absolute Core Strategy ET.. | 0.00 % | 0.00 % |
+0.11 (+0.54%) |
USD 0.09B |
| TDOC:CA | TD Global Healthcare Lead.. | 0.00 % | 0.00 % |
+0.01 (+0.54%) |
CAD 0.09B |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -1.02% | 55% | F | 34% | F | ||
| Dividend Return | 2.54% | 86% | B+ | 40% | F | ||
| Total Return | 1.52% | 55% | F | 30% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -0.92% | 58% | F | 35% | F | ||
| Dividend Return | 2.54% | 86% | B+ | 41% | F | ||
| Total Return | 1.62% | 58% | F | 31% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -27.57% | 42% | F | 21% | F | ||
| Dividend Return | 10.89% | 100% | F | 35% | F | ||
| Total Return | -16.68% | 46% | F | 18% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -2.87% | 35% | F | 20% | F | ||
| Dividend Return | -0.36% | 39% | F | 19% | F | ||
| Total Return | 2.52% | 100% | F | 57% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 19.66% | 94% | A | 56% | F | ||
| Risk Adjusted Return | -1.82% | 39% | F | 19% | F | ||
| Market Capitalization | 103.90B | 96% | N/A | 98% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
